EI funded project aims to improve the efficacy of pulmonary drug delivery systems in ICUs
Aerogen, the world leader in acute care aerosol drug delivery, has today announced a €300k research agreement with Tyndall National Institute, UCC, Ireland’s leading deep tech ICT research facility. Funded by the Enterprise Ireland (EI) Innovation Partnership Programme, this collaboration focuses on technology for improving aerosol drug delivery.
Headquartered in Galway, Aerogen is one of Ireland’s leading indigenous medtech companies, specialising in the design, manufacture and marketing of aerosol drug delivery systems. The company’s transformative aerosol technology is used to treat patients on life support ventilation in Intensive Care Units (ICUs) in 75 countries. Aerogen products have been instrumental in helping patients worldwide to recover from Covid-19 during the current pandemic.
“This new collaboration with Tyndall focuses on next-generation deep tech for acute care aerosol drug delivery systems,” explained Dr Ronan MacLoughlin, Senior Science Manager at Aerogen. “Tyndall’s track record of delivering engineering innovation in commercial research will help us pioneer, next generation solutions in critical care settings.”
“This is what deep tech ICT for Health is all about,” agreed Tyndall researcher Dr Oskar Z. Olszewski. The two-year project is focused on the re-development of a mechanical component used to nebulise pulmonary drugs from liquid form into an aerosol of tiny droplets capable of being inhaled directly into a patient’s lungs.
“The Irish MedTech sector is a very exciting area in which Tyndall leads,” elaborated Prof William Scanlon, CEO, Tyndall National Institute. “Work we do here, accelerates the commercialisation of research outcomes and maximises the economic and social benefits from government investment like the EI Innovation Partnership programme.”
“Over the past 10 years, Tyndall has built a strong reputation in deep tech ICT for medtech applications,” added Carlo Webster, Senior Strategic Business Development Executive at Tyndall. “Supporting innovative, indigenous Irish companies like Aerogen helps to keep Tyndall at the forefront of innovation.”
Aerogen is the world’s leading medical device company specializing in the design, manufacture and commercialization of aerosol drug delivery systems. Aerogen’s patented vibrating mesh technology turns liquid medication into a fine particle mist, gently and effectively delivering drugs to the lungs of patients . Aerogen’s innovative products, such as the Aerogen® Solo and Aerogen® Ultra, significantly improve aerosol drug delivery resulting in better patient care throughout the Hospital across all ages.
The Aerogen Solo is a closed-system, single patient use (vibrating mesh) aerosol drug delivery technology offering superior performance across all hospital ventilation modalities. Designed for the safety of both the patient and the caregiver, Aerogen’s closed-circuit design enables the only global aerosol drug delivery system which mitigates the transmission of patient-generated infectious aerosol during ventilation.
Founded in Galway, Ireland in 1997, Aerogen has grown to become the global leader in high performance aerosol drug delivery and has partnered its technology with the leading mechanical ventilation companies1. Aerogen technology is used by millions of patients and caregivers in over 75 countries worldwide.
About Tyndall National Institute
Tyndall is a leading European research centre in integrated ICT (Information and Communications Technology) materials, devices and systems. It is one of Ireland’s six National Labs, specialising in both electronics and photonics. Tyndall works with industry and academia to transform research into products in its core market areas of electronics, communications, energy, health, agri-tech & the environment. With a network of over 200 industry partners and customers worldwide, they are focused on delivering human and economic impact from excellence in research. A research flagship of University College Cork, Tyndall is home to a research community of 600 people of 52 nationalities.